Treatment and prevention of adhesions
AssigneesHadasit, Agricultural Research Organization
InventorsMark Pines, Arnon Nagler
Life of this patent
Estimating the term…
Abstract
An inhibitor of adhesion formation which can be used to prevent adhesions within the abdominal cavity, particularly following surgical intervention, trauma or inflammation in the area is disclosed. Specifically, the most preferred compound of the present invention, Halofuginone, can be used to prevent collagen deposition from occurring within the peritoneum after surgical intervention, thereby inhibiting adhesion formation. Halofuginone, and related compounds, are useful in the prevention and treatment of both inflammatory and surgically induced adhesions, and in the treatment of congenital adhesions.
Claims20
A method for the treatment of an adhesion in a subject, the adhesion forming a fibrous bridge between normally separated tissues, with the proviso that the adhesion is not a fibrous peritendinous adhesion, the method comprising the step of administering to the subject a pharmaceutically effective amount of a compound having a formula:
- ##STR12## wherein:
- R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;
- R.sub.2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and
- R.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, such that the fibrous bridge is treated.
A method for substantially preventing formation of an adhesion in a subject, the adhesion forming a fibrous bridge between normally separated tissues, with the proviso that the adhesion is not a fibrous peritendinous adhesion, the method comprising the step of administering to the subject a pharmaceutically effective amount of a compound having a formula:
- ##STR13## wherein:
- R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;
- R.sub.2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and
- R.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, such that the formation of the fibrous bridge is prevented.
A method for inhibition of formation of an adhesion in a subject for treatment substantially before performance of a surgical procedure, the adhesion forming a fibrous bridge between normally separated tissues, with the proviso that the adhesion is not a fibrous peritendinous adhesion, the method comprising the step of administering to the subject a pharmaceutically effective amount of a compound having a formula:
- ##STR14## wherein:
- R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;
- R.sub.2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and
- R.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, such that the formation of the fibrous bridge is prevented.
A method for treatment of an inflammatory disease characterized by formation of an adhesion, the adhesion forming a fibrous bridge between normally separated tissues, with the proviso that the adhesion is not a fibrous peritendinous adhesion, the method comprising the step of administering to the subject a pharmaceutically effective amount of an antibiotic with a pharmaceutically effective amount of a compound having a formula:
- ##STR15## wherein:
- R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;
- R.sub.2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and
- R.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, such that the fibrous bridge is treated.
Dependencies are inferred from the claim text.